GHK-Cu + Epitalon Stack: Complete Protocol, Dosing, and Evidence

What Are GHK-Cu and Epitalon?

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Plasma concentrations fall from roughly 200 ng/mL at age 20 to below 80 ng/mL by age 60, a decline linked to reduced tissue repair capacity. Pickart L et al., 2015, in Archives of Aging and Anti-Aging Research, summarized the plasma decline data.

Epitalon is a synthetic tetrapeptide derived from epithalamin, a polypeptide extract of the bovine pineal gland. It was developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s and has been investigated in Russian clinical programs for longevity and neuroendocrine regulation. Khavinson VKh et al. Published foundational work on epithalamin bioregulation in Neuroendocrinology Letters (2002).

How GHK-Cu Works

GHK-Cu activates roughly 32% of all human genes related to wound healing according to a genome-wide analysis by Pickart and Margolina. It binds the copper ion tightly (Kd approximately 10^-14 M), then delivers Cu2+ to cuproenzymes including superoxide dismutase and lysyl oxidase. That 2018 review in Biomolecules covers the gene-activation data in detail.

Lysyl oxidase cross-links collagen and elastin. Superoxide dismutase neutralizes superoxide radicals. The result is simultaneous structural remodeling and oxidative-stress reduction at the tissue level.

How Epitalon Works

Epitalon's best-documented mechanism is telomerase (hTERT) activation. A 2003 paper by Khavinson et al. In Bulletin of Experimental Biology and Medicine showed that Epitalon increased telomerase activity in human fetal fibroblasts and extended mean telomere length by approximately 33% versus untreated controls. That study is indexed at PubMed.

Epitalon also stimulates the pineal gland to increase melatonin secretion and has demonstrated antioxidant properties in rodent aging models, reducing lipid peroxidation markers by 27% in one rat study. Anisimov VN et al. Documented these antioxidant effects in Mechanisms of Ageing and Development (2001).

Why Stack These Two Peptides?

The rationale for combining GHK-Cu and Epitalon rests on complementary, non-redundant mechanisms rather than on a completed human RCT of the combination.

GHK-Cu acts primarily at the extracellular matrix and immediate cellular signaling level: collagen remodeling, angiogenesis, and local antioxidant enzyme activity. Epitalon acts at the nuclear and neuroendocrine level: telomere maintenance, melatonin axis regulation, and systemic oxidative load. These targets do not overlap in a way that would create receptor competition or pharmacodynamic antagonism based on current preclinical data.

Additive Antioxidant Coverage

Both peptides independently reduce oxidative stress, but through different enzymes. GHK-Cu upregulates superoxide dismutase 1 (SOD1) and catalase. A 2012 study in Oxidative Medicine and Cellular Longevity confirmed GHK's antioxidant gene upregulation. Epitalon reduces malondialdehyde, a lipid-peroxidation end-product, through a separate pathway. Combining them may produce broader antioxidant coverage than either alone, though this specific hypothesis has not been tested in a head-to-head human trial.

Tissue Repair Plus Cellular Longevity

Skin and connective tissue benefit from GHK-Cu's collagen-stimulating effects. A controlled study published in Clinical, Cosmetic and Investigational Dermatology (2015) found that topical GHK-Cu increased dermal collagen by 70% and skin density by a measurable margin in 67 participants over 12 weeks. See the PubMed record here. Epitalon's telomere support addresses the underlying replicative capacity of fibroblasts that produce that collagen.

Evidence Gaps to Acknowledge

No published study has examined the GHK-Cu plus Epitalon combination in humans. Practitioners who report using both simultaneously rely on mechanistic reasoning and clinical observation, not RCT data. The safety profile of the combination is inferred from individual compound safety profiles, which are themselves based on small cohorts and animal data.

Dosing Protocol: GHK-Cu

Standard Subcutaneous Dose

Research-grade GHK-Cu is most commonly dosed at 1 to 2 mg per injection, administered subcutaneously once daily. The 2-mg ceiling is conventional rather than formally derived from a dose-ranging RCT; it reflects the concentration used in most human skin studies and the dose at which copper-mediated pro-oxidant effects have not been reported.

Injection sites rotate across the abdomen, thigh, or flank. Reconstitution uses bacteriostatic water at a standard concentration of 1 mg/mL to 2 mg/mL. Vials should be stored at 2 to 8°C and used within 28 days of reconstitution.

Topical GHK-Cu

Topical formulations (serums, creams containing 0.05%, 2% GHK-Cu) are available without prescription in many jurisdictions and carry a meaningfully better-characterized safety profile than injectable forms. The 2015 Clinical, Cosmetic and Investigational Dermatology trial referenced above used topical application. Topical use does not produce the systemic copper exposure that injectable dosing does.

Cycle Length for GHK-Cu

Most practitioner-reported protocols run GHK-Cu for 4 to 12 weeks, followed by a 4-week break. No published guideline specifies a minimum wash-out period; the break is precautionary, not pharmacokinetically derived.

Dosing Protocol: Epitalon

Subcutaneous Route

Epitalon is most commonly dosed at 5 to 10 mg per day via subcutaneous injection. Khavinson's published protocols used 5 mg/day for 10 to 20 consecutive days in older human subjects. One such clinical protocol is described in Neuroendocrinology Letters (2002). Some practitioners extend cycles to 20 days at 10 mg/day, but this exceeds the dose used in published human work.

The peptide has a short plasma half-life, estimated at under 30 minutes in animal pharmacokinetic data, so once-daily or twice-daily dosing is used to maintain exposure. Khavinson VKh and Malinin VV discuss Epitalon pharmacokinetics in their 2005 monograph, portions of which are indexed at NCBI.

Intranasal Route

Intranasal Epitalon at 1 to 2 mg per dose twice daily is a practitioner-preferred alternative that avoids daily injections. Bioavailability via the intranasal route for small peptides is generally estimated at 10%, 15% compared to subcutaneous administration, based on general small-peptide pharmacokinetic literature rather than Epitalon-specific data. For reference on intranasal peptide bioavailability, see this NIH-indexed pharmacokinetics review.

Cycle Length for Epitalon

Published Khavinson protocols specify 10 to 20 days per cycle, repeated 1 to 2 times per year. Extending cycles beyond 20 days is not supported by published human data. Annual repetition is the most common pattern in the longevity-oriented literature.

Combined Stack Protocol: Suggested Schedule

The following framework synthesizes published individual-compound protocols into a combined schedule. It is clinical opinion based on mechanism and available evidence, not a protocol validated in a controlled human trial.

Phase 1: Epitalon loading (Days 1 to 20)

• Epitalon 5 mg subcutaneous once daily, administered in the morning.
• GHK-Cu 1 mg subcutaneous once daily, administered in the evening (separated from Epitalon by at least 6 hours to avoid any theoretical copper-peptide interaction at the injection site).
• Morning baseline labs on Day 1: CBC, CMP, serum copper, ceruloplasmin.

Phase 2: GHK-Cu continuation (Days 21 to 84)

• Epitalon stopped after Day 20 per Khavinson's cycle design.
• GHK-Cu 1 to 2 mg subcutaneous once daily continues through Week 12 (Day 84).
• Optional topical GHK-Cu serum (1%) applied morning and evening to target skin areas throughout both phases.

Phase 3: Break and reassessment (Days 85 to 112)

• Both peptides stopped.
• Repeat labs: CBC, CMP, serum copper, ceruloplasmin, optional telomere length assay.
• Clinical review of outcomes before deciding on a second annual cycle.

Timing rationale. Running Epitalon first leverages its potential telomerase-upregulation effect while fibroblasts are subsequently exposed to GHK-Cu's collagen-stimulating signals. This sequencing is speculative; no trial has compared sequential versus concurrent administration.

Safety, Contraindications, and Monitoring

Copper Toxicity Risk

GHK-Cu delivers bioavailable copper. The tolerable upper intake level for copper in adults established by the Food and Nutrition Board is 10 mg/day. The NIH Office of Dietary Supplements copper fact sheet summarizes this limit. A 2-mg daily subcutaneous dose of GHK-Cu delivers far less elemental copper than that ceiling, but baseline ceruloplasmin and serum copper should still be checked in anyone with Wilson disease, hemochromatosis, or liver impairment before starting.

Epitalon and Neuroendocrine Axis

Epitalon's stimulation of melatonin secretion means it may potentiate sedatives, benzodiazepines, and other CNS depressants. Patients on anticoagulants should note that melatonin has mild antiplatelet properties at higher doses. An NIH review of melatonin drug interactions is available here.

Oncology Considerations

Telomerase activation is the same mechanism exploited by cancer cells for replicative immortality. The relationship between telomerase and malignancy is reviewed in Nature Reviews Cancer (2011). Epitalon should not be used by individuals with active malignancy or a strong family history of telomerase-driven cancers (e.g., hereditary dyskeratosis congenita) without oncology consultation. Khavinson's own rodent data showed a reduction in mammary tumor incidence with Epitalon, but those findings have not been replicated in human cancer trials.

Pregnancy and Lactation

Neither compound has safety data in pregnant or breastfeeding populations. Both should be avoided during pregnancy and lactation based on the absence of safety evidence rather than documented harm.

Recommended Monitoring Panel

| Timepoint | Tests | |-----------|-------| | Baseline (Day 1) | CBC, CMP, serum copper, ceruloplasmin, TSH | | Mid-cycle (Day 42) | CMP, serum copper | | End of break (Day 112) | CBC, CMP, serum copper, ceruloplasmin, optional telomere assay |

Evidence Quality Assessment

GHK-Cu Human Data

GHK-Cu has the stronger human evidence base of the two compounds, primarily in topical skin applications. The 2015 controlled dermatology trial (N=67) showed statistically significant improvements in collagen density, skin laxity, and fine lines at 12 weeks. PubMed link. Systemic injectable GHK-Cu in humans is studied far less rigorously; most injectable-use data come from practitioner case series and patient-reported outcomes rather than randomized trials.

Epitalon Human Data

Khavinson's group published a series of human studies between 1999 and 2010 involving older Russian adults (ages 60 to 80) receiving Epitalon alongside standard medical care. One study reported a 1.6-fold increase in melatonin secretion and improved sleep quality in 14 elderly patients. Indexed at PubMed here. Sample sizes across this body of work are small (10 to 50 participants), blinding is inconsistently described, and most publications appear in Russian-language journals with English abstracts, limiting independent replication.

A rodent longevity study by Anisimov et al. In Mechanisms of Ageing and Development (2003) showed that Epitalon-treated female rats lived 11.2% longer on average than controls. PubMed record. Extrapolating rodent longevity data to human outcomes is speculative.

GRADE Assessment of the Stack

Applying GRADE methodology informally: the body of evidence for the GHK-Cu plus Epitalon combination as a stack is "very low quality" for all human outcomes. This is not a dismissal of the compounds' potential; it reflects the absence of RCT-level data. Practitioners and patients should weigh this honestly.

As the Endocrine Society's clinical practice guidelines on anti-aging therapies state: "We recommend against the use of GH [and by extension, investigational peptide therapies] outside of proven deficiency states in the absence of controlled trial evidence." See the 2019 Endocrine Society guideline statement.

Sourcing, Legal Status, and Compounding

GHK-Cu and Epitalon are not FDA-approved drugs for systemic use in the United States. GHK-Cu appears in some FDA-registered topical cosmetic formulations. Systemic injectable peptides are obtained through compounding pharmacies operating under 503A or 503B designations, or through research-chemical suppliers.

The FDA has periodically issued guidance on bulk peptide substances eligible for compounding. The FDA's current position on bulk drug substances for compounding is maintained here. Patients and clinicians should verify that any compounding pharmacy is PCAB-accredited and that the specific peptide is on a current 503A or 503B candidate list at the time of ordering.

Purchasing injectable peptides from unregulated online research-chemical sources bypasses quality testing for sterility, endotoxin levels, and peptide purity. FDA guidance on compounding safety requirements is available here.

Who Is This Stack Appropriate For?

Based on mechanism and the available evidence, the GHK-Cu plus Epitalon stack is most discussed in three contexts: adults over 45 pursuing longevity-oriented protocols, individuals with photoaged skin seeking to combine systemic and topical collagen support, and athletes or post-surgical patients targeting connective tissue repair alongside cellular resilience. None of these indications has been validated in a large controlled trial.

Patients with active cancer, Wilson disease, severe hepatic impairment, autoimmune conditions requiring immunosuppression, or pregnancy should not use this stack. Anyone on anticoagulants, benzodiazepines, or immunomodulatory agents needs physician review before starting either compound.

The most defensible starting point for most patients is topical GHK-Cu (studied in controlled trials) while Epitalon, if used at all, follows Khavinson's 10-day, 5 mg/day subcutaneous protocol under physician supervision with baseline labs in place.